Holen Sie sich die Stockscreener-App
9.51
1.04%
-0.10
Handel nachbörslich:
9.61
0.10
+1.05%
Schlusskurs vom Vortag:
$9.61
Offen:
$9.35
24-Stunden-Volumen:
39,475
Relative Volume:
0.32
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-9.77%
1M Leistung:
-27.29%
6M Leistung:
+27.31%
1J Leistung:
+27.48%
1-Tages-Spanne:
$9.05
$9.5546
1-Wochen-Bereich:
$9.05
$10.48
52-Wochen-Spanne:
$3.62
$13.67
Direxion Daily Pharmaceutical Medical Bull 3 X Etf Stock (PILL) Company Profile
Firmenname
Direxion Daily Pharmaceutical Medical Bull 3 X Etf
Sektor
Branche
Telefon
-
Adresse
-
Compare PILL vs VTI, SPY, IVV, VB, QQQ
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PILL
Direxion Daily Pharmaceutical Medical Bull 3 X Etf
|
9.51 | 0 | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
323.18 | 417.53B | 0 | 0 | 0 | 0.00 |
SPY
State Street Spdr S P 500 Etf Trust
|
653.18 | 372.57B | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
656.23 | 253.41B | 0 | 0 | 0 | 0.00 |
VB
Vanguard Small Cap Etf
|
263.51 | 160.59B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
583.98 | 124.43B | 0 | 0 | 0 | 0.00 |
Direxion Daily Pharmaceutical Medical Bull 3 X Etf Aktie (PILL) Neueste Nachrichten
Behavioral Patterns of PILL and Institutional Flows - Stock Traders Daily
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart
Medical Biomimetics Market Forecast to Reach USD 85.94 Billion by 2031 Driven by Tissue Engineering Demand, Regenerative Medicine Adoption, and Expanding Clinical Applications - Barchart.com
How Is West Pharmaceutical's Stock Performance Compared to Other Healthcare Stocks? - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart.com
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight | Kartos Therapeutics, AOP Orphan Pharmaceuticals - Barchart
Dr. Ranjan Rajbanshi Scholarship for Medical Students Announces National Essay Competition for Aspiring Healthcare Professionals - Barchart.com
(PILL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies - Barchart.com
Pharmaceutical Drug Delivery Market Projected to Reach $2,546.0 Billion by 2029 with Advancements in Targeted Therapies - Barchart.com
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Barchart.com
Paroxysmal Nocturnal Hemoglobinuria Market: Expanding Revenue Landscape to 2034 – DelveInsight | Alexion Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, AKARI Therapeutics, AstraZeneca - Barchart.com
Multiple Myeloma Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Barchart.com
How (PILL) Movements Inform Risk Allocation Models - Stock Traders Daily
Hypertension Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - Barchart.com
Student-Led Nonprofit Empathy in Medicine Initiative Launches National Chapter for High School and College Students - Barchart.com
North America Biomarkers Market to Reach $42.25 Billion by 2030, Driven by Precision Medicine and Safety Biomarker Adoption - Barchart.com
Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value - Barchart.com
XLRE Trails the S&P 500 by 5% Despite Lower Interest Rates That Were Supposed To Help - AOL.com
Trading Systems Reacting to (PILL) Volatility - Stock Traders Daily
6 Best Defense ETFs to Watch in 2026 - The Motley Fool
5 Small-cap Biotech ETFs to Watch - Investing News Network
How Direxion Daily Pharmaceutical & Medical Bull 3x Shares (PILL) Affects Rotational Strategy Timing - Stock Traders Daily
CURE: Benefits And Caveats Of The Leveraged Healthcare ETF (NYSEARCA:CURE) - Seeking Alpha
Short Interest in Direxion Daily Pharmaceutical & Medical Bull 3X Shares (NYSEARCA:PILL) Drops By 37.4% - Defense World
ENN Energy (OTCMKTS:XNGSF) Trading Down 1.6% – Here’s Why - Defense World
Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchart
(PILL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
What You Need To Know Ahead of Baxter International's Earnings Release - Barchart
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - AOL.com
Why Vera Therapeutics Stock Zoomed Higher Today - AOL.com
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' - Benzinga
GE HealthCare’s Q4 2025 Earnings: What to Expect - Barchart.com
Esophageal Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharma, Amgen, AstraZeneca, Symphogen, Hoffmann-La Roche - Barchart.com
Responsive Playbooks and the PILL Inflection - Stock Traders Daily
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference - Barchart.com
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 - Barchart.com
What Investors Should Know About a $163K AnaptysBio Insider Sale - AOL.com
Clarity Wealth Advisors LLC Reduces Holdings in iShares Global Healthcare ETF $IXJ - Defense World
Q4 Earnings: Beat, Miss, or Market Whiplash? - Direxion
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - AOL.com
Understanding the Setup: (PILL) and Scalable Risk - Stock Traders Daily
U.S. Equity ETF Tracker | Storage price hikes spread, Micron hits new highs; 2x Long MU ETF rises over 7% - news.futunn.com
U.S. Stock ETF Tracker | Storage price hikes spread, Micron hits new highs, 2x Long MU ETF rises over 7% - 富途牛牛
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Barchart.com
Direxion Daily Pharmaceutical & Medical Bull 3X Shares declares quarterly distribution of $0.0327 - MSN
Why (PILL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Trump, nine pharmaceutical companies strike deal to cut prices - Yahoo! Finance Canada
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared - MSN
Finanzdaten der Direxion Daily Pharmaceutical Medical Bull 3 X Etf-Aktie (PILL)
Es liegen keine Finanzdaten für Direxion Daily Pharmaceutical Medical Bull 3 X Etf (PILL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
1.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):